<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5283606 Figure_1-A</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>The syntheses of the ligands PR-924, 9, 14, 16, 17 and 18 have been described previously (de Bruin et al, 2014). All ligands share the peptide scaffold shown in the upper left corner with P1, P2 and P3 side chains and an N-cap; they are equipped with a l-Ala (stereochemistry (S)) or d-Ala (stereochemistry (R)) residue at P3 (red) and either an N-acylmorpholine or a 3-methyl-1H-indene group (green). Furthermore, compounds differ in their P2 residue (either methoxytyrosine or tryptophane; blue). Inhibitor 9, also termed LU-015i, is endowed with an exceptional cyclohexyl residue (gray), which is associated with increased selectivity for human &#946;5i.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_2-A</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Inhibition of human &#946;5c and &#946;5i by ONX 0914 and PR-924. IC50 values are deduced from the fitted data.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_3-E</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Serial dilutions of yeast cells were spotted on YPD plates and grown for 2 days either at 30 &#176;C or 37 &#176;C. Mutant yeasts are significantly retarded in growth and show increased temperature sensitivity.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_3-F</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 3-F</infon>
    <infon key="sourcedata_figure_dir">Figure_3-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Surface illustration of the yCP. The &#946;5 and &#946;6 subunits are depicted in dark gray, with the residue ranges that correspond to mammalian &#946;5 and &#946;6 subunits in the chimeric proteasomes highlighted in gold and blue, respectively. The &#946;5' and &#946;6' subunits of the second &#946;-ring are hidden on the back of 20S proteasome.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_4-A</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Superposition of the &#946;5i/&#946;6 active sites of genuine mouse iCP and the h&#946;5i/h&#946;6 human/yeast chimera illustrates that Met45 adopts the same 'open' conformation in both structures. Amino acid side chains important for substrate binding are depicted as sticks. The catalytic Thr1 is colored in black. Met31, the single amino acid difference between mouse and human &#946;5i active sites, is highlighted in green.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_4-B</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Superposition of the genuine mouse and the human chimeric &#946;5c/&#946;6 active sites according to panel A proves the proper orientation of Met45 in the 'closed' conformation.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_4-C</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Superposition of the &#946;5c/&#946;6 and &#946;5i/&#946;6 active sites of the natural mouse cCP and iCP according to panel A. Note the distinct conformations of Met45 (Huber et al, 2012).</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_4-D</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 4-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Superposition of the h&#946;5c/h&#946;6 and the h&#946;5i/h&#946;6 chimeric proteasomes confirm the distinct positions of Met45 analogously to the natural mouse subunits shown in panel C.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_5-A</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Complex structures of the human &#946;5c/&#946;6 (left) and &#946;5i/&#946;6 (right) chimeric proteasomes with PR-924. The ligand binds in a linear (l) manner to the &#946;5c/&#946;6 substrate binding channel, but in a kinked (k) conformation to the &#946;5i/&#946;6 active site. The 2FO-FC electron density maps for the ligands bound to Thr1 of the chimeric &#946;5 active sites are shown as blue meshes contoured at 1&#963;. The inhibitor and Thr1 have been omitted for phasing.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_5-B</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Comparison of the conformations of ONX 0914, PR-924, 14, 16, 17 and 18 bound to the chimeric h&#946;5/h&#946;6 substrate binding channels. The l amino acid compounds ONX 0914 and 14 display a linear (l) binding mode to the h&#946;5c/h&#946;6 (left) and the h&#946;5i/h&#946;6 (right) chimeras, whereas the ligands 16 and 17 (P3-d-Ala and morpholine cap) adopt a kinked (k) conformation in both &#946;5 substrate binding channels. Remarkably, the orientation of PR-924 and its analogue 18 (P3-d-Ala and 3-methyl-1H-indene cap) in the h&#946;5c/h&#946;6 chimera (and in WT y&#946;5; see Appendix Figure S5)) differs from that observed with the h&#946;5i/h&#946;6 chimera. Note that the inhibitors are rotated by about 45 &#176; compared to panel A.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_6-A</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Complex structures of the mouse chimeric proteasome (left) and the h&#946;5i-V31M/h&#946;6 mutant (right) with PR-924 visualize the kinked (k) orientation. The 2FO-FC electron density maps for the ligands bound to Thr1 of the chimeric &#946;5 active sites are depicted according to Fig 5A. Steric hindrance of Met31 (green) with the bulky 3-methyl-1H-indene cap is indicated by black double arrows.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_6-B</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Superposition of inhibitors bound to the mouse chimeric proteasome (left) and the h&#946;5i-V31M/h&#946;6 mutant (right). Compounds display the same binding modes (kinked (k) or linear (l)) to the m&#946;5i/m&#946;6 active site as to the corresponding human &#946;5i/&#946;6 subunit (Fig. 5) and to the h&#946;5i-V31M/h&#946;6 mutant. Note that the inhibitors are rotated by about 45&#176; compared to panel A.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_6-C</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 6-C</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Superposition of chimeric mammalian and WT yeast &#946;5 active sites bound to the P3-d-Ala compounds PR-924 and 18. The nucleophilic Thr1 is depicted as well as the S1 pocket forming residues 31 and 45. Residue 31 impacts on the position of the 3-methyl-1H-indene cap of PR-924 and 18. Due to steric hindrance, the N-cap is shifted in the mouse and in the h&#946;5i-V31M/h&#946;6 chimera compared to the h&#946;5i/h&#946;6 mutant proteasome crystal structures (black double arrow). Note that the structures are rotated by 90&#176; compared to panel B.</text>
    </passage>
  </document>
  <document>
    <id>5283606 Figure_7-A</id>
    <infon key="sourcedata_document">2346</infon>
    <infon key="doi">10.15252/embj.201695222</infon>
    <infon key="pmc_id">5283606</infon>
    <infon key="figure">Figure 7-A</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A</infon>
    <passage>
      <offset>0</offset>
      <text>ONX 0914 binds in a linear mode to all active sites. Changing the stereochemistry at the P3 site from l-Ala (S) to d-Ala (R) leads to a kinked conformation in the &#946;5 substrate binding channels (compound 16). Substitution of the morpholine cap of 16 by a larger 3-metyhl-1H-indene moiety yields PR-924 and results in different inhibitor conformations at the y&#946;5/h&#946;5c and the mammalian &#946;5i active sites. Hereby, the selectivity for h&#946;5i over h&#946;5c is drastically increased (IC50 ratio h&#946;5c/h&#946;5i: 255) compared to ONX 0914 (IC50 ratio h&#946;5c/h&#946;5i: 20) and compound 16 (IC50 ratio h&#946;5c/h&#946;5i: 5.2, Fig 2). Residue Met31 of m&#946;5i sterically hinders the kinked binding mode of PR-924, thereby creating 7-fold selectivity for human &#946;5i.</text>
    </passage>
  </document>
</collection>
